Company Overview of Intersect ENT, Inc.
Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
1555 Adams Drive
Menlo Park, CA 94025
Founded in 2003
Key Executives for Intersect ENT, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $332.4K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $202.8K
Chief Operating Officer and Senior Vice President
Total Annual Compensation: $290.2K
Vice President of Sales
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2014.
Intersect ENT, Inc. Key Developments
Intersect ENT, Inc. Enrolls First Patient in Pivotal Study to Evaluate the Nova Sinus Implant
Jul 8 15
Intersect ENT, Inc. announced the enrollment of the first patient in the company's pivotal study of its latest bioabsorbable steroid releasing sinus implant, currently called NOVA. NOVA is designed to mechanically prop sinuses open while delivering anti-inflammatory medication following surgical interventions such as sinus surgery in the operating room or in-office sinus dilation. NOVA's unique hourglass shape and lower profile is designed to allow for placement in the smaller frontal and maxillary sinus openings, and may expand the applicable patient population for steroid releasing implants. The NOVA study is a prospective, randomized, blinded, multi-center trial of 80 patients designed to assess implant safety and efficacy. The company is conducting the NOVA trial as a second cohort of patients of the PROGRESS study. The first cohort of the PROGRESS study was an 80-patient prospective, randomized blinded multi-center trial to assess the safety and efficacy of the PROPEL® mini drug eluting implant to improve outcomes following frontal sinus surgery and was designed to support an expanded indication for PROPEL mini, currently approved for use in the ethmoid sinus. In addition to announcing the initiation of patient enrollment in the NOVA study, the company also announced that enrollment in the PROPEL mini cohort of the study has recently been completed.
Intersect ENT, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 09:30 AM
Jun 18 15
Intersect ENT, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 09:30 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Jeryl L. Hilleman, Chief Financial Officer and Principal Accounting Officer, Lisa D. Earnhardt, Chief Executive Officer, President and Director.
Intersect ENT, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 11:30 AM
Jun 3 15
Intersect ENT, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 11:30 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|